Quinagolide (Norprolac®): A novel non-ergot prolactin inhibitor

Drugs of Today

Volumn 32, Issue 1, 1996, Pages 77-104

  Brownell, Judith ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; PROLACTOSTATIN; QUINAGOLIDE;

BODY WEIGHT; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; MALE; MASTALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PREGNANCY; PROLACTINOMA; REVIEW; VERTIGO; VOMITING;

EID: 0029926590     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1996.32.1.355024     Document Type: Review

References (71)

1. Daughaday, W.H. The anterior pituitary. In: William's Textbook of Endocrinology. Wilson, J.D., Foster, D.W. (Eds.). W.B. Saunders: Philadelphia 1985, 583-5.
2. von Werder, K., Fahlbusch, R., Riosk, H.K. Macroprolactinomas: Clinical and therapeutic aspects. In: Prolactin and Prolactinomas. Tolis, G. (Ed.). Raven Press: New York 1983, 415-27.
3. Grossman, A., Besser, G.M. Prolactinomas. Brit Med J 1985, 290: 182-4.
4. Schlechte, J.A., Sherman, B., Martin, R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 1983, 56: 1120-3.
5. Leong, D.A., Frawley, L.S., Neill, J.D. Neuroendocrine control of prolactin secretion. Ann Rev Physiol 1983, 45: 109-28.
6. Thorner, M.O., Shran. H.F., Evans, W.S., Rogol, A.D., Morris, J.L., MacLeod, R.M. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women. A study of serum prolactin and bromocriptine levels after acute and chronic administration. J Clin Endocrinol Metab 1980, 50: 1026-33.
7. Flückiger, E. The pharmacology of bromocriptine. In: Pharmacological and Clinical Aspects of Bromocriptine (Parlodel). Bayliss, R.I.S., Turner, P., Maclay, W.P. (Eds,). MCS Consultants: Tunbridge Wells 1976, 12-26.
8. Bucher, T.J. Mechanism of the antihypertensive effect of bromocriptine in the rat. Naunyn-Schmied Arch Pharmacol 1982, 319: R62.
9. Nordmann, R., Petcher, T.J. Octahydrobenzo[g]quinolines: Potent dopamine agonists which show the relationship between ergolines and apomorphine. J Med Chem 1985, 28: 367-75.
10. 2-agonist CV 205-502 and related octahydrobenzo[g]quinolines. Drugs Fut 1988, 13(10): 951-9.
11. Flückiger, E.W., Briner, U., Bucher, T. et al. Pharmacodynamic actions of octahydrobenzo[g]quinoline, CV 205-502, in animals. In: CV 205-502: Clear Progress in Dopamine Agonist Therapy. Selected Literature Overview. Brownell, J., Flückiger, E. (Eds.). Medicom Europe: Bussum 1989, 1: 23-35.
12. Trouillas, J., Chevallier, P., Claustrat, B. et al. Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology 1994, 134: 401-10.
13. Mekler, P., Bürki, K. Comparison of the effect of dopaminergic compounds on rat pituitary hormone-mRNA and -release levels in vivo and in vitro. Experientia 1986, 42: 690.
14. Davis. J.R.E., Vidai, M.E., Wilson, E.M., Sheppard, M.C. Suppression of prolactin release and mRNA accumulation by two novel dopamine agonist agents. Acta Endocrinol 1989, 120: 672-6.
15. Venetikou, M.S., Burrin, J.M., Woods, C.A., Yeo, T.H., Brownell, J., Adams, E.F. Effects of two novel dopaminergic drugs, CV 205-502 and CQP 201-403, on prolactin and growth hormone secretion by human pituitary tumours in vitro. Acta Endocrinol 1987, 116: 287-92.
16. Flückiger, E.W., Briner, U., Bucher, T. et al. Pharmacodynamic actions of the octahydrobenzo[g]quinoline CV205-502. 1st International Round Table Conference. Besser, G.M., Lamberts, S.W.J. (Eds.). Medicom Europe: Bussum 1990, 10-22.
17. Coward, D.M., Markstein, R. Dopamine receptor subtypes: Their involvement in motor regulation. In: Function and Dysfunction in the Basal Ganglia. Franks, A.J., Ironside, J.W., Mindham, R.H.S., Smith, R.J., Spokes, E.G.S., Winlow, W. (Eds.). Manchester University Press: Manchester 1990, 35-42.
18. 2 agonist CV 205-502 in bovine retina homogenates. Biochem Pharmacol 1992, 43: 1882-4.
19. 2 receptors in the rat brain: Autoradiographic visualization using a high-affinity selective agonist ligand. J Neurosci 1987, 7: 1352-60.
20. 3H] N-0437. Neurosci Lett 1987, 83: 259-63.
21. Seiler, M.P., Markstein, R., Walkinshaw, M.D., Boelsterli, J.J. Characterization of dopamine receptor subtypes by comparative structure-activity relationships: Dopaminomimetic activities and solid-state conformation of monohydroxy-1. 2, 3, 4, 4a, 5, 10, 10a-octahydrobenz[g]quinolines and its implications for a rotamer-based dopamine receptor model. Mol Pharmacol 1989, 35: 643-51.
22. 3H] CV 205-502. Brain Res 1988, 440: 123-32.
23. Stoof, J.C., Kebabian, J.W. Two dopamine receptors: Biochemistry, physiology and pharmacology. Life Sci 1984, 35: 2281-96.
24. Quinagolide file. Sandoz Pharma Ltd. Doc. No. 701-269, 1992.
25. Quinagolide file. Sandoz Pharma Ltd. Doc. No. 065984.01, 1992.
26. Gaillard, R., Nordmann,R., Petcher, T.J., Brownell, J. A novel octahydrobenzo[g]quinoline, CV 205-502, with potent dopamine agonist properties. In: Endocrinology '85. Molinatti, G.M., Martini, L. (Eds.). Elsevier Science Publishers: Amsterdam 1986, 305-8.
27. Gaillard, R.C., Brownell, J. Hormonal effects of CV 205-502, a novel octahydrobenzo[g]quinoline with potent dopamine agonist properties. Life Sci 1988, 43: 1355-62.
28. Delitala, G. Dopamine and TSH secretion in man. Lancet 1977, ii: 760-1.
29. Boyd, A.E., Lebovitz, H.E., Pfeiffer. J.B. Stimulation of growth hormone secretion of L-DOPA. New Engl J Med 1970, 283: 1425-9.
30. Brown, W.A., van Woert, M.H., Ambani, L.M. Effect of apomorphine on growth hormone release in humans. J Clin Endocrmol Metab 1973, 37: 463-5.
31. Tolis, G., Pinter, E.J., Friesen. H. The acute effect of 2-bromo-a-ergocryptine (CB-154) on anterior pituitary hormones and free fatty acids in man. Int J Clin Pharmacol 1975, 12: 281-3.
32. Gaillard, R.C., Abeywickrama, K., Brownell, J., Muller, A.F. Specific effect of CV 205-502, a potent non-ergot dopamine agonist, during a combined anterior pituitary function test. J Clin Endocrinol Metab 1989, 68: 329-35.
33. Besses, G.S., Burrow, G.N., Spaulding, S.W., Donabedian, R.K. Dopamine infusion acutely inhibits the TSH and prolactin response to TRH. J Clin Endocrinol Metab 1975, 41: 985-7.
34. Burrow, G.N., May, P.B., Spaulding, S.W., Donabedian, R.R. TRH and dopamine interactions affecting pituitary hormone secretion. J Clin Endocrinol Metab 1978, 45: 65-72.
35. Rasmussen, C., Bergh, T., Wide, L., Brownell, J. CV 205-502: A new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol 1987, 26: 321-6.
36. Gaillard, R., Brownell, J., Abeywickrama, K. CV 205-502: A new long-acting drug for the treatment of hyperprolactinemia. In: New Trends in Brain and Female Reproductive Function. Genazzani, A.R., Montemagno, U., Nappi, C., Petraglia, F. (Eds.). CIC Edizioni Internazionali: Rome 1988, 153-6.
37. van der Heiden, P.F.M., Lappöhn, R.E., Corbey, R.S., de Goeij, W.B.K.M.V., Brownell, J., Rolland, R. The effectiveness, safety and tolerability of CV 205-502 in hyperprolactinaemic women: A 12-month study. Fertil Steril 1989, 52: 574-83.
38. Rasmussen, C., Bergh, T., Wide, L., Brownell, J. Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia. Clin Endocrinol 1988, 29: 271-9.
39. Rasmussen, C., Brownell, J., Bergh., T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinol 1991, 125: 170-6.
40. Quinagolide file. Sandoz Pharma Ltd. Doc. No. 0603.256, 1992.
41. van der Heijden, P.F.M., de Wit, W., Brownell, J., Schoemaker, J., Rolland, R. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynaecol Reprod Biol 1991, 40: 111-8.
42. Homburg, R., West, R., Brownell, J., Jacobs, H.S. A double-blind study comparing a new nonergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol 1990, 32: 565-71.
43. Lappoehn, R.E., van de Wiel, H.B.M., Brownell, J. The effects of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia. Fertil Steril 1992, 58: 321-7.
44. Quinagolide file. Sandoz Pharma Ltd. Doc. No. 065701.01, 1995.
45. Kvistborg, A., Halse, J., Bakke, S., et al. Long-term treatment of macroprolactinomas with CV 205-502. Acta Endocrinol 1993, 128: 301-7.
46. van der Lely, A.J., Brownell, J., Lamberts, S.W.J. The efficacy and tolerability of CV 205-502 (a non-ergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991, 72: 1136-41.
47. Vance, M.L., Lipper, M., Klibanski, A., Biller, B.M.K., Samaan, N.A., Molitch, M.E. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Int Med 1990, 112: 668-73.
48. Serri, O., Beauregard, H., Lesage, J. et al. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 1990, 71: 682-7.
49. Khalfallah, Y., Claustrat, B., Grochowicki, M. et al. Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human prolactinomas. J Clin Endocrinol Metab 1990, 71: 354-9.
50. van't Verlaat, J.W., Croughs, R.J.M., Brownell, J. Treatment of macroprolactinomas with a new non-ergot long-acting dopaminergic drug, CV 205-502. Clin Endocrinol 1990, 33: 619-34.
51. Crottaz, B., Uske, A., Reymond, M.J. et al. CV 205-502 treatment of macroprolactinomas. J Endocrinol Invest 1991, 14: 757-62.
52. Barnett, P.S., Dawson, J.M., Butler, J., Coskeran, P.B., Maccabe, J.J., McGregor, A.M. CV 205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man. Clin Endocrinol 1990, 33: 307-16.
53. Chung, G., Atkin, S.L., Diver, M., White, M.C. CV 205-502 in the management of women intolerant of bromocriptine. J Endocrinoi 1991, 129 (Suppl.): 196.
54. McNally, P.G., Price, D.E., Hewlett, T.A. Efficacy and tolerability of quinagolide (CV 205-502) in patients with prolactin (PRL) secreting tumours intolerant and/or resistant to bromocriptine. J Endocrinol 1991, 129 (Suppl.): 299.
55. Newman, C.B., Hurley, A.M., Kieinberg, D.L. Effects of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin Endocrinol 1989, 31: 391-400.
56. Shoham, Z., Homburg, R., Jacobs, H.S. CV 205-502-effectiveness, tolerability, and safety over 24-month study. Fertil Steril 1991, 55: 501-6.
57. Abrahamson, M.J., Handler, L., Isaacs, M. Effects of CV 205-502 on growth hormone and prolactin secretion in acromegaly and hyperprolactinaemic states including micro- and macroprolactinomas. J Endocrinol Invest 1991, 14 (Suppl. 1): 105.
58. Beckers, A., Ghuysen, A.-E., Verhelst, J. et al. Le traitement des prolactinomes par un nouvel agoniste dopaminergique (le CV 205-502): Résultats chez 48 patients. Méd Hygiene 1992, 50: 2064-9.
59. Merola, B., Sarnacchiaro, F., Colao, A. et al. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994, 8: 175-81.
60. Svoboda, T., Luger, A., Knosp, E., Geyer. G. Prolactinom-Behandlung mit einem neuen Dopaminagonisten. Dtsch Med Wschr 1991, 116: 1224-7.
61. Brue, T., Pellegrini, I., Gunz, G. et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992, 74: 577-84.
62. von Werder, K.V., Fahlbusch, R., Landgraf, R., Pickardl, C.R., Rjosk, H.K., Scriba, P.C. Treatment of patients with prolactinomas. J Endocrinol Invest 1978, 1: 47-59.
63. Wass, J.A.H., Williams, J., Charlesworth, M. Bromocriptine in management of large pituitary tumours. Brit Med J 1982, 284: 1908-11.
64. Molitch, M.E., Elton, R.I., Blackwell, R.O. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985, 60: 698-705.
65. Pellegrini, I., Rasolojanahary, R., Gunz, G. et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989, 69: 500-9.
66. van Loon, G.R. Bromocriptine-induced orthostatic hypotension. Clin Invest Med 1980, 28: 425-34.
67. Kuchel, O., Buu, N.T., Hamet, P. Orthostatic hypotension: A posture-induced hyperdopaminergic state. Amer J med Sci 1985, 289: 3-11.
68. Quinagolide file. Sandoz Pharma Ltd. Doc. No. 065120.01, 1992.
69. Brownell, J., Krupp, P., Monka, C. Norprolac® in pregnancy. Brit Endocrine Soc Meet (Warwick, UK) 1995.
70. Beischer, N.A., Mackay, E.V. Obstetrics and the Newborn: An Illustrated Textbook. Baillere Tindall: London 1986.
71. Rosenberg. A.A., Thilo, H. The newborn infant. In: Current Pediatric Diagnosis & Treatment. Hay, W.W., Groothuis, J.R., Hayward, A.R., Levin, M.J. (Eds.). Prentice-Hall 1995, 9-64.